• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前哨淋巴结活检在乳腺导管原位癌(DCIS)及伴微浸润的DCIS中的价值。

The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast.

作者信息

van la Parra R F D, Ernst M F, Barneveld P C, Broekman J M, Rutten M J C M, Bosscha K

机构信息

Department of Surgery, Jeroen Bosch Ziekenhuis, P.O. Box 90153, 5200 ME 's-Hertogenbosch, The Netherlands.

出版信息

Eur J Surg Oncol. 2008 Jun;34(6):631-5. doi: 10.1016/j.ejso.2007.08.003. Epub 2007 Sep 11.

DOI:10.1016/j.ejso.2007.08.003
PMID:17851019
Abstract

AIM

Ductal carcinoma in situ (DCIS) refers to the preinvasive stage of breast carcinoma and should not give axillary metastases. Its diagnosis, however, is subject to sampling errors. The role of sentinel lymph node biopsy (SLNB) in management of DCIS or DCISM (with microinvasion) remains unclear. The purpose of this study was to review our experience with SLNB in DCIS and DCISM.

METHODS

A review of 51 patients with a diagnosis of DCIS (n=45) or DCISM (n=6), who underwent SLNB and a definitive breast operation between January 1999 and December 2006, was performed.

RESULTS

In 10 patients (19.6%) definitive histology revealed an invasive carcinoma. SLN (micro)metastases were detected in 5 out of 51 patients, of whom 2 had a preoperative diagnosis of grade III DCIS and 3 of DCISM. Three patients (75%) had micrometastases (< 2 mm) only. In 2 patients, histopathology demonstrated a macrometastasis (> 2 mm). All 5 patients underwent axillary dissection. No additional positive axillary lymph nodes were found.

CONCLUSIONS

In case of a preoperative diagnosis of grade III DCIS or a grade II DCIS with comedo necrosis and DCIS with microinvasion, an SLNB procedure has to be considered because in almost 20% of the patients an invasive carcinoma is found after surgery. In this case the SLNB procedure becomes less reliable after a lumpectomy or ablation has been performed. SLN (micro)metastases were detected in nearly 10% of the patients. The prognostic significance of individual tumour cells remains unclear.

摘要

目的

导管原位癌(DCIS)是指乳腺癌的浸润前期,不应出现腋窝转移。然而,其诊断存在抽样误差。前哨淋巴结活检(SLNB)在DCIS或伴有微浸润的DCIS(DCISM)治疗中的作用仍不明确。本研究的目的是回顾我们在DCIS和DCISM中进行SLNB的经验。

方法

回顾性分析了1999年1月至2006年12月期间51例诊断为DCIS(n = 45)或DCISM(n = 6)并接受了SLNB及确定性乳房手术的患者。

结果

10例患者(19.6%)的最终组织学检查显示为浸润性癌。51例患者中有5例检测到前哨淋巴结(微)转移,其中2例术前诊断为III级DCIS,3例为DCISM。3例患者(75%)仅出现微转移(<2 mm)。2例患者组织病理学显示为大转移(>2 mm)。所有5例患者均接受了腋窝清扫术,未发现其他腋窝阳性淋巴结。

结论

对于术前诊断为III级DCIS或伴有粉刺样坏死的II级DCIS以及伴有微浸润的DCIS患者,应考虑进行SLNB,因为几乎20%的患者术后会发现浸润性癌。在这种情况下,在进行肿块切除或消融术后,SLNB的可靠性会降低。近10%的患者检测到前哨淋巴结(微)转移。单个肿瘤细胞的预后意义仍不明确。

相似文献

1
The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast.前哨淋巴结活检在乳腺导管原位癌(DCIS)及伴微浸润的DCIS中的价值。
Eur J Surg Oncol. 2008 Jun;34(6):631-5. doi: 10.1016/j.ejso.2007.08.003. Epub 2007 Sep 11.
2
Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion?前哨淋巴结活检:高危导管原位癌及伴有微浸润的导管原位癌患者是否需要进行该项检查?
Ann Surg Oncol. 2000 Oct;7(9):636-42. doi: 10.1007/s10434-000-0636-2.
3
Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida.导管原位癌前哨淋巴结活检:佛罗里达大学的一种不断发展的方法。
Breast J. 2005 Nov-Dec;11(6):394-7. doi: 10.1111/j.1075-122X.2005.00128.x.
4
Ductal carcinoma in situ: value of sentinel lymph node biopsy.导管原位癌:前哨淋巴结活检的价值
J Surg Oncol. 2006 Oct 1;94(5):426-30. doi: 10.1002/jso.20578.
5
Factors predicting microinvasion in Ductal Carcinoma in situ.导管原位癌微浸润的预测因素。
Asian Pac J Cancer Prev. 2014;15(1):55-60. doi: 10.7314/apjcp.2014.15.1.55.
6
Sentinel lymph node biopsy for localised ductal carcinoma in situ?局部导管原位癌的前哨淋巴结活检?
Breast. 2005 Dec;14(6):520-2. doi: 10.1016/j.breast.2005.08.007. Epub 2005 Sep 26.
7
Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.原位导管癌且前哨淋巴结阳性的女性患者的结局:一项多机构审计
Ann Surg Oncol. 2007 Oct;14(10):2911-7. doi: 10.1245/s10434-007-9414-8. Epub 2007 Jun 28.
8
Outcome of patients with ductal carcinoma in situ and sentinel node biopsy.导管原位癌和前哨淋巴结活检患者的预后。
Ann Surg Oncol. 2012 Jul;19(7):2345-51. doi: 10.1245/s10434-012-2287-5. Epub 2012 Mar 7.
9
Selective approach to radionuclide-guided sentinel lymph node biopsy in high-risk ductal carcinoma in situ of the breast.乳腺高危导管原位癌放射性核素引导前哨淋巴结活检的选择性方法。
Nucl Med Commun. 2011 Nov;32(11):1084-7. doi: 10.1097/MNM.0b013e328349eafc.
10
Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy.导管原位癌的粗针活检诊断:前哨淋巴结活检的一项指征
Curr Surg. 2005 Mar-Apr;62(2):253-7. doi: 10.1016/j.cursur.2004.09.011.

引用本文的文献

1
Toward Exempting from Sentinel Lymph Node Biopsy in T1 Breast Cancer Patients: A Retrospective Study.关于T1期乳腺癌患者免于前哨淋巴结活检的回顾性研究。
Front Surg. 2022 Jun 28;9:890554. doi: 10.3389/fsurg.2022.890554. eCollection 2022.
2
Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.前哨淋巴结活检在导管原位癌患者中的应用:系统评价和荟萃分析。
BJS Open. 2022 Mar 8;6(2). doi: 10.1093/bjsopen/zrac022.
3
Breast Lesions Diagnosed as Ductal Carcinoma by Ultrasound-Guided Core Needle Biopsy: Risk Predictors for Concomitant Invasive Carcinoma and Axillary Lymph Node Metastasis.
经超声引导下粗针穿刺活检诊断为导管癌的乳腺病变:伴发浸润性癌和腋窝淋巴结转移的风险预测因素
Front Oncol. 2021 Sep 10;11:717198. doi: 10.3389/fonc.2021.717198. eCollection 2021.
4
The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ.MRI 与临床病理特征在预测经活检证实的导管原位癌中浸润性成分的作用。
BMC Med Imaging. 2020 Aug 12;20(1):95. doi: 10.1186/s12880-020-00494-z.
5
Ductal Carcinoma In Situ of the Breast: Perspectives on Tumor Subtype and Treatment.乳腺导管原位癌:肿瘤亚型和治疗的观点。
Biomed Res Int. 2020 May 27;2020:7251431. doi: 10.1155/2020/7251431. eCollection 2020.
6
Risk factors for lymph node metastasis and the impact of adjuvant chemotherapy on ductal carcinoma in situ with microinvasion: a population-based study.淋巴结转移的危险因素及辅助化疗对伴有微浸润的导管原位癌的影响:一项基于人群的研究。
Onco Targets Ther. 2018 Dec 13;11:9071-9080. doi: 10.2147/OTT.S186228. eCollection 2018.
7
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes.乳腺原位癌:肿瘤亚型、治疗及预后的观察性研究
Oncotarget. 2017 Jan 10;8(2):2361-2371. doi: 10.18632/oncotarget.13785.
8
Breast US in patients with breast cancer presenting as only microcalcifications on mammography: can US differentiate ductal carcinoma in situ from invasive cancer?乳腺钼靶检查仅表现为微小钙化的乳腺癌患者的乳腺超声检查:超声能否鉴别导管原位癌和浸润性癌?
J Med Ultrason (2001). 2014 Jan;41(1):39-44. doi: 10.1007/s10396-013-0474-z. Epub 2013 Jul 9.
9
Sentinel lymph node biopsy in patients with breast ductal carcinoma : Chinese experiences.乳腺导管癌患者前哨淋巴结活检:中国经验
Oncol Lett. 2015 Sep;10(3):1932-1938. doi: 10.3892/ol.2015.3480. Epub 2015 Jul 10.
10
Extent of microinvasion in ductal carcinoma in situ is not associated with sentinel lymph node metastases.导管原位癌的微浸润范围与前哨淋巴结转移无关。
Ann Surg Oncol. 2014 Oct;21(10):3330-5. doi: 10.1245/s10434-014-3920-2. Epub 2014 Aug 5.